



# Increase in manufacturing capacity for COVID-19 vaccine from BioNTech/Pfizer

News 09/09/2021

EMA's human medicines committee (<u>CHMP</u>) has approved additional manufacturing sites for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.

One site, located in Frankfurt am Main, Germany, is operated by Sanofi-Aventis Deutschland GmbH. The other in Hameln, also in Germany, is operated by Siegfried Hameln GmbH. Both sites will manufacture finished product.

These sites will provide up to 50 million additional doses in 2021.

These recommendations do not require a <u>European Commission decision</u> and the sites can become operational immediately.

EMA is in continuous dialogue with all <u>marketing authorisation holders</u> of COVID-19 vaccines as they seek to expand their production capacity for the supply of vaccines. The Agency provides guidance and advice on the evidence required to support and expedite applications to add new sites or increase the capacity of existing sites for the manufacture of high-quality COVID-19 vaccines.

### Related content %

• Comirnaty: EPAR

· Comirnaty: Paediatric investigation plan

## Related content

- Coronavirus disease (COVID-19)
- COVID-19: latest updates
- COVID-19 vaccines: key facts
- COVID-19 vaccines: authorised
- COVID-19 vaccines: development, evaluation, approval and monitoring

## Contact point 1

#### **EMA press office**

Tel. +31 (0)88 781 8427

E-mail: press@ema.europa.eu

Follow us on Twitter @EMA\_News [2]

#### **CONTACT**

European Medicines Agency Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands

Tel: +31 (0)88 781 6000

For delivery address, see:

How to find us

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

© 1995-2021 European Medicines Agency

European Union agencies network



An agency of the European Union

